High Altitude Cerebral Edema

Dexamethasone 3.3 mg/mL solution for injection

Dexamethasone

Sodium Chloride 0.9% w/v solution for injection

Placebo

University Hospitals Coventry and Warwickshire NHS Trust

Spectroscopic and Diffusion Weighted Analysis of the Effects of Dexamethasone on High Altitude Cerebral Oedema (HACE)

Differences in oedematous changes in the brain and spinal cord as measured by changes in brain and spinal cord MRI imaging

To assess the role of primary blood brain barrier breakdown in hypoxic cytotoxic oedema as measured by variation in serum markers

Change in glial specific (GFAP) and non-glial specific (purines) serum biomarkers from baseline and at 8, 11, 22 and 26 hours post hypoxic insult

To develop a hypoxic spinal cord model for use in future research looking into complex vascular surgery.

Individual participant data will not be shared with other researchers

Double-blind, randomised controlled trial

The participant, Investigator supervising the visit and the Outcome Assessor will be blinded to the treatment allocation

To Evaluate the Effect of Therapy With IT MTX on the Disease Course of Patients With Progressive MS

12.5 mg of methotrexate diluted to a concentration of up to 4 mg/mL in 0.9 percent sodium chloride with 4 mg Dexamethasone via lumbar puncture needle.

Intrathecal methotrexate

Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study

Disability will be measured every visit by the Multiple Sclerosis Functional Composite (MSFC)

adverse events will be followed until resolution. Serious adverse events will be reported to the IRB within 24 hours of noticed.

(Composite measure) We will measure new gd+ enhancing lesions, number of lesions, brain and upper spinal cord atrophy and cortical thickness and compare these measure between the time before and after treatment along. Overall each participant will undergo 5 scans , the first before treatment installation and then before each treatment . one scan will be done 3 month after the last treatment

(Composite measure) Cerebrospinal fluid (CSF) sample will be obtained and analyze for parameters including cell count and differential, protein and glucose concentration, oligoclonal bands, IgG concentration, cellular analysis by flow cytometry for CD3+, CD20+, CD14+ cell subsets, and measurement of several soluble mediators such as: CXCL13, CD23, light chains, TNFa, IFNg, IL-17, IL-2, IL-10, BDNF and Neurofilaments will be studied by ELISA

michal roll

Director R&D Division

Tel-Aviv Sourasky Medical Center

Patients will be treated with dasatinib monotherapy 100mg daily. At four weeks patients will be re-evaluated. Patients with less than a partial response will receive fludarabine (orally 40mg/daily for 3 days q28) in addition to dasatinib.

Chronic Lymphocytic Leukemia

Chemo-refractory CLL patients will be treated with dasatinib monotherapy 100mg daily.Patients with less than a partial response at 4 weeks will receive fludarabine (orally 40mg/daily for 3 days q28) in addition to dasatinib for a maximum of 6 cycles. Patients with at least a partial response will continue dasatinib monotherapy. Patients that receive monotherapy after the initial 28 days and that develop progressive disease will 'cross-over' to the combination treatment.

purine/headache

Spectroscopic and Diffusion Weighted Analysis of the Effects of Dexamethasone on High Altitude Cerebral Oedema (HACE)

Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study

Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease

Baz done ki pi konplè remèd fèy medsin te apiye nan syans